Yesterday we saw an announcement of an important manufacturing partnership in the Europe. It is the one between SOMAÍ Pharmaceuticals and Canna Forest. The collaboration intends to use SOMAÍ’s modern facility to manufacture extracted cannabis Active Pharmaceutical Ingredients (APIs) and products that are EU-GMP certified.
Known for its dedication to providing the best medical-grade pharmacological applications, SOMAÍ Pharmaceuticals is about to use its experience in the extraction, development, formulation, and distribution of cannabinoid medicines authorised by the EU GMP pharmaceutical market. This tactical partnership with Canna Forest, a duly registered Portuguese manufacturer and distributor of medical cannabis products, strengthens SOMAÍ’s standing as a major participant in the rapidly expanding cannabis-based healthcare industry.
About both sides
SOMAÍ Pharmaceuticals is a well-established EU-GMP company committed to transforming healthcare with innovative cannabis-based therapies. Focuses on the extraction, development, formulation, and distribution of cannabinoid medicines authorised by the EU GMP pharmaceutical market. That is why SOMAÍ is leading the way in the advancement of medical-grade applications of cannabis.
Canna Forest, however, is a Portuguese company. It has an authorisation to produce and distribute medical cannabis products. It has a 10,000 square metre production space, on-site GACP post-harvest facilities, and GMP I and II agreements. Canna Forest is a company that specialises in developing genetics for the best cannabis products that are legal in Europe. They offer a variety of products, such as seeds, clones, oils, distillates, CBD, and THC that are EU-GMP grade.
The manufacturing agreement between SOMAÍ Pharmaceuticals and Canna Forest follows SOMAÍ’s recent EU Good Manufacturing Practices approval in September. As per the terms of this agreement, EU-GMP extracted APIs for distribution in Australia will be produced from high-THC medical cannabis flower from Canna Forest by SOMAÍ. There are plans to sell much more in 2024. So, 240 kg of premium cannabis extracts have already been set aside for sale in Germany and Australia.
The CEO of SOMAÍ Pharmaceuticals, Michael Sassano, highlighted SOMAÍ’s commitment to helping regional Portuguese growers and expressed his satisfaction in working with Canna Forest’s skilled staff. Sassano said:
“We will continue to innovate products with many different extract APIs to help patients find the right mix for them.”
The best value chain of medicinal extracts on the worldwide market is one that Teresa Faisca, CEO of Canna Forest LDA, expressed her joy in adding to. Faisca gave gratitude to SOMAÍ Pharmaceuticals’ excellent staff and installations for the collaboration’s success.
This partnership is a major step forward in the development of cannabis-based drugs. It also demonstrates both businesses’ dedication to providing patients all around the world with high-quality medical treatments. Please visit SOMAÍ Pharmaceuticals’ website for further details.